Biologics and challenges ahead for the physician

Journal, Indian Academy of Clinical Medicine

Volumn 7, Issue 4, 2006, Pages 334-343

  Tandon, Vishal R ^a   Mahajan, Annil ^a   Khajuria, Vijay ^a   Kapoor, V ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

Biologics; Challenges; Interleukin antagonist; TNF alpha

Indexed keywords

ABATACEPT; ADALIMUMAB; ALPHA INTERFERON; AMG 714; ATLIZUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DRUG ANTIBODY; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 6 ANTIBODY; ISONIAZID; LANERCEPT; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 10; RIBAVIRIN; RIFAMPICIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABSCESS; ANKYLOSING SPONDYLITIS; ANTIBODY PRODUCTION; ANTIGENICITY; APLASTIC ANEMIA; BACTERIAL ARTHRITIS; BACTERIAL INFECTION; BEHCET DISEASE; BIOLOGICAL THERAPY; BREAST FEEDING; CARDIOPULMONARY ARREST; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; COUGHING; CROHN DISEASE; DEMYELINATING DISEASE; DIARRHEA; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECCHYMOSIS; ERYTHEMA; FLU LIKE SYNDROME; HEADACHE; HEART FAILURE; HEPATITIS C; HISTOPLASMOSIS; HUMAN; INFECTION; INFECTION PREVENTION; INFLAMMATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; JUVENILE RHEUMATOID ARTHRITIS; LISTERIOSIS; LIVER FAILURE; LOW DRUG DOSE; LUPUS LIKE SYNDROME; LYMPHOMA; MUCKLE WELLS SYNDROME; MULTIPLE SCLEROSIS; MYELITIS; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NEWBORN DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; OSTEOMYELITIS; PANCYTOPENIA; PARKINSON DISEASE; PHYSICIAN; PREGNANCY; PROSTHESIS INFECTION; PSORIATIC ARTHRITIS; RASH; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SEPSIS; SIDE EFFECT; SINUSITIS; SOLID TUMOR; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC MYCOSIS; TOXOPLASMOSIS; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD; WEGENER GRANULOMATOSIS;

EID: 33845355101     PISSN: 09723560     EISSN: 09723560     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Paul BJ. Rheumatoid arthritis- A therapeutic review. Calicut Medical Journal 2004; 2 (2): e8.
2. Kavanaugh AF. Anti-tumour necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998; 24: 593-614.
3. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22.
4. Sharma PK, Hota D, Pandhi P. Biologics in Rheumatoid Artheitis. J Assoc Physic India 2004; 52: 231-6.
5. Cole P, Rabasseda X. The soluble tumour necrosis factor receptor etanercept: a new strategy for the treatment of autoimmune rheumatic disease. Drug today 2004; 40 (4): 281-324.
6. McCormack PL, Wellington K. Etanercept: In ankylosing spondylitis. Biodrugs 2004; 18 (3): 199-206.
7. Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B. Adalimumab in clinical practice outcome in 70 Rheumatoid Artheritis patients, including patients with or without previous anti-TNF exposure. Rheumatol 2005; 44: 1026-31.
8. Ken JB. Biologic therapies in Rheumatoid arthritis. Current Rheu Report 1999; 1: 157-63.
9. Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004; 63: 149-55.
10. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D et al. Adalimumab, a fully human anti tumour necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30: 2563-71.
11. Klareskog L, Van Der HD, de Jager JP, Gough A, Kalden J, Malaise M et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
12. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-72.
13. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab therapy in patients with psoriatic arthritis: 24 week results of a phase III study [abstract]. Arthritis Rheum 2004; 50: 4097.
14. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48: 1667-75.
15. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-93.
16. Culy CR, Keating GM. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 2002; 62: 2493-537.
17. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 2005; 32: 98-105.
18. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomised, double-blind, placebo-controlled study. J Hepatol 2005; 42: 315-22.
19. Serio RN. Infliximab treatment of sarcodosis. Ann Pharmacother 2003; 37: 577-81.
20. Lamprecht P, Voswinkel J, Lilenthal T et al. Effectiveness of TNF- alpha blockade with infliximab in refractory Wegener's disease. Rheumatology (Oxoford) 2002; 41: 1303-7.
21. Narayanan K, Anand KP. Two year follow up of infliximab therapy in inflammatory arthritis. J Ind Rheumatol Assoc 2005; 13 (suppl 1): 7-8.
22. Grover R, Kapoor S, Marwaha V, Malaviya A, Gupta R, Kumar A. Clinical experience with infiximab in spondyloarthropathy: An open label study on fourteen patients. J Indian Rheumatol Assoc 2005; 13: 78-82.
23. Shalini S, Singh VK, Chaturvedi V. Strategy to prevent tuberculosis during anti TNF therapy in juvenile Anklosing- spondylitis with low dose infliximab without loading schedule: A one year open label study of toxicity and efficacy in 15 patients. J Indian Rheumatol Assoc 2005; 13 (supplement): 10-5
24. Ramnath Misra, Sanjib Amin, Joshi VR, URK Rao, Aggarwal A, Patil S, Shovani V. Open-label Evaluation of the Efficacy and Safety of Etanercept in Rheumatoid arthritis. JIRA 2005; 13 (4): 131-4.
25. Furst DE, Wallis R, Beenhouwer D et al. Tumour necrosis factor antagonists and granulomatous infections: mechanisms of action. Semin Arthritis Rheum 2005; (in press).
26. Centers for Disease Control and Prevention. Tuberculosis associated with blocking agents against tumour necrosis factor-alpha - California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004; 53: 683-6.
27. Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumour necrosis factor inhibitor. Clin Infect Dis 2004; 39: 295-9.
28. Schiff M, van der Putter LB, Breedveld FC, Kupper H, Fischkoff S et al. Rates of infection in adalimumab rheumatoid arthritis clinical trials [abstract]. Ann Rheum Dis 2003; 62: abstract no 184.
29. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 2005; 44: 714-20.
30. Ehlers S. Tumour Necrosis factor and its blockade in granulomatous infections: Differential modes of action of infliximab and etanercept. Clinical Infectious Diseases 2005; 41: S199-203.
31. Algood HMS, Lin PL, Flynn JL. Tumour necrosis factor and chemokine interactions in the formation and maintainance of Granulomas in tuberculosis. Clincal Infectious Disease 2005; 41: S189-93.
32. Wallis RS, Broder M, Wong J, Lee A, Hoq L. Reactivation of latent Granulomatous infections by infliximab. Clinical Infectious Disease 2005; 41: S194-8.
33. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious disease associated with tumour necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261-5.
34. Wallis RS, Broder MS, Wong JY, Beenhouwer DO. Granulomatous infectious due to tumour necrosis factor blockade correction. Clin Infect Dis 2004; 39: 1254-5.
35. Agarwal V. Anti Tumour Necrosis Factor- Alpha Therapy: Caution is needed in Indian context. J Indian Rheumatol Assoc 2005; 13: 75-7.
36. British Thoracic Society Standards of Care Committ. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-{alpha} treatment. Thorax 2005; 60: 800-5.
37. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S221-S247.
38. CDC. Adverse Event Data and Revised American Thoracic Society/CDC recommendations against the use of rifampicin and pyrazinamide for treatment of latent tuberculosis infection. Morbidity and Mortality Weekly Report 2003; 52: 735-9.
39. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-93.
40. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumour necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261-5.
41. Jacobsson LTH, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T et al. No increase of severe infections in RA patients treated with TNF-blockers [abstract]. Ann Rheum Dis 2005; 64 (suppl III): 461.
42. Filler SG, Yeaman MR, Sheppard DC. Tumour necrosis factor inhibition and invasive fungal infections. Clincal Infectious Disease 2005; 41: S208-12.
43. Torres D, Janot L, Quesniaux VFJ, Grivennikov SI, Maillet I, Sedgwick JD, Ryffel B, Erard F. Membrane Tumour Necrosis Factor Confers Partial Protection to Listeria Infection. Am J Pathol 2005; 167: 1677-87.
44. Young JD, McGwire BS, Callegari PE. Infliximab and Reactivation of Cerebral Toxoplasmosis. N Engl J Med 2005; 353: 1530-1.
45. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson I, Saxne T et al. TNF blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699-703.
46. Asklin J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L et al. Characteristics of malignant lymphomas following TNF-blockade. Preliminary results of an ongoing Swedish monitoring-programme of biologics in RA [abstract]. Ann Rheum Dis 2005; 64 (suppl III): 449.
47. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumour necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004 ; 50 (6): 1740-51.
48. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001; 44: 1149-54.
49. Negrusz-Kawecka M. The role of TNF-alpha in the aetiopathogenesis of heart failure. Pol Merkuriusz Lek 2002; 12 (67): 69-72.
50. Sarzi-Puttini P, Atzeni F, Doria A, Iaccarino L, Turiel M. Tumour necrosis factor-alpha, biologic agents and cardiovascular risk. Lupus 2005; 14 (9): 780-4.
51. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev 2005; 4 (3): 153-61.
52. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumour necrosis factor therapy. Am J Med 2004; 116 (5): 305-11.
53. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Anti-TNF therapy against congestive heart failure investigators. Randomised, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumour necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107 (25): 3133-40.
54. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005; 64: 403-7.
55. Christopher L, Wigley F. TNF-alpha antagonists induce lupus-like syndrome in patients scleroderma and polyarthritis [abstract]. Arthritis Rheum 2002; 46 (suppl): S358.
56. Mohan N,Edward ET, Cupps TR et al.Demyelination occurring during antitumor necrosis factor alpha therapy for inflammatory arthritis. Arthritis Rheum 2001; 44: 2862-9.
57. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-5.
58. Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatolog Treat 2003; 14: 229-32.
59. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomised, double-blind, placebo-controlled study. J Hepatol 2005; 42: 315-22.
60. Gordon DA, Klinkhoff AV. Anti cytokine therapy: In (eds) Edwaed DH et al. Kelley's Texbook of Rheumatology, elseviers Saunder 2005; 1: 944-50.
61. Shrim A, Koren G. Tumour necrosis factor alpha and use of infliximab. Safety during pregnancy. Can Fam Physician 2005; 51: 667-8.
62. Sills ES, Perloe M, Tucker MJ, Kaplan CR, Palermo GD. Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: a recombinant fusion anti-cytokine treatment for rheumatoid arthritis. Am J Reprod Immunol 2001; 46 (5): 366-8.
63. Kavanaugh A. Health economics: implications for novel antirheumatic therapies. Ann Rheum Dis 2005; 64 (Suppl 4): iv 65-9.
64. Merkesdal S, Zeidler H. TNF-blocking therapy in rheumatoid arthritis and ankylosing spondylitis: why is cost-effectiveness a major issue? Curr Rheumatol Rep 2005; 7 (4): 254-8.
65. Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. Refractory adult onset Still's disease successfully treated with anakinra. Ann Rheum Dis 2005; 64: 647-8.
66. Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 2005; 52: 1283-6.
67. Wendling D, Racadot E, Wijdenes J. Treatment of severe Rheumatoid Artheritis by anti- interleukin-6 monoclonal antibody. J Rheumatol 1993; 20 (2): 259-62.
68. Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H. Toxicity , Pharmacokinetics and dose - finding study of repetitive treatment with humanised anti-interleukin 6 receptor antibody MRA in Rheumatoid Arthritis Phase I/II clinical study. J Rheumatol 2003; 30: 1426-35.
69. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrery, KremerJ et al. Abatacept for Rheumatoid Arthritis refractory to tumour necrosis factor-α inhibition. N Engl J Med 2005; 353 (11): 1114-23.
70. Singh R, Robinson DB, Gabalawy HSEI. Emerging biologic therapies in rheumatoid arthritis: cell targets and cytokines. Current Opinion Rheumatol 2005; 2 (1): 38-43.
71. Choy EH, Hazleman B, Smith M, Moss K, Lisi L,Scott DG et al. Efficacy of a novel pegylated humanised anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: A phase ii double-blind, randomised dose-escalating trial. Rheumatol (Oxford) 2002; 41 (10): 1133-7.
72. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNF-α blockers in adults with Rheumatoid Arthritis (update of previous guidelines of april 2001). Rheumatol 2005; 44: 157-63.